A recent study from the perspective of the Chinese healthcare system investigated the cost-effectiveness of first-line erlotinib compared with platinum-doublet chemotherapy in advanced EGFR mutation positive lung cancer patients based on outcomes from the OPTIMAL trial (42). The gene discussed is EGFR; the disease is lung cancer.